822:
anti–JC virus antibodies. When the risk of PML was evaluated according to three risk factors, it was lowest among the patients who had used natalizumab for the shortest periods, those who had used few if any immunosuppressant drugs to treat MS in the past, and lastly who were negative for anti–JC virus antibodies. The incidence of PML in the low risk group was estimated to be 0.09 cases, or less, per 1000 patients. Patients who had taken natalizumab for longer, from 25 to 48 months, who were positive for anti–JC virus antibodies, had taken immunosuppressants before the initiation of natalizumab therapy had the highest risk of developing PML. Their risk is fully 123 times higher than the low risk group. (incidence, 11.1 cases per 1000 patients ). While none of them had taken the drug in combination with other disease-modifying treatments, previous use of MS treatments increases the risk of PML between 3 and 4-fold. In 2016, EMA recommended all people taking natalizumab should undergo full MRI scans at least once a year due to concerns of progressive multifocal leukoencephalopathy (PML). In addition, more frequent MRI scans (e.g. every 3 to 6 months) should be performed using simplified protocols should be considered for those at higher risk of PML.
1143:. In February 2005, four months after its approval, natalizumab was withdrawn voluntarily by the manufacturer after two cases of progressive multifocal leukoencephalopathy. Groups representing individuals with MS lobbied to have the drug returned to the US market and in June 2006, after recommendation by an advisory committee and a review of two years of safety and efficacy data, the FDA re-approved natalizumab for patients with all relapsing forms of MS (relapse-remitting, secondary-progressive, and progressive-relapsing) as a
1086:, indications of PML infection appeared only after natalizumab monotherapy was re-introduced. No deaths from progressive multifocal leukoencephalopathy have been linked to natalizumab when it was not combined with other immune-modulating drugs and other rates of opportunistic infections are not increased in patients taking natalizumab possibly due to the drug's mechanism of action. Other than a prior history of PML, there is no known method to identify patients at risk of developing PML. Natalizumab's label indicates that it is
624:
914:
138:
25:
117:
6318:
1775:
1192:(EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tyruko, intended for the treatment of multiple sclerosis. The applicant for this medicinal product is Sandoz GmbH. Tyruko was approved for medical use in the European Union in September 2023.
772:
Natalizumab offers a limited improvement in efficacy compared to other treatments for multiple sclerosis, but due to the lack of information about long-term use, as well as potentially fatal adverse events, reservations have been expressed over the use of the drug outside of comparative research with
768:
for the treatment of multiple sclerosis and Crohn's disease. It is indicated to treat clinically isolated syndrome – a single, first occurrence of multiple sclerosis symptoms; relapsing-remitting disease – a type of multiple sclerosis that occurs when people have episodes of new neurological symptoms
816:
It was first observed in seven patients who received natalizumab in late 2008; three cases were noted in clinical trials in 2006 leading to the drug being temporarily pulled from the market; two cases were reported to the FDA in August 2008; and two cases were announced in
December 2008. By January
743:
often used in the treatment of multiple sclerosis. After a review of safety information and no further deaths, the drug was returned to the US market in 2006 under a special prescription program. As of June 2009, ten cases of PML were known. However, twenty-four cases of PML had been reported since
720:
Natalizumab, is a monoclonal antibody which targets a protein called α4β1 integrin on white blood cells involved in inflammation. By attaching to integrin, natalizumab is thought to stop white blood cells from entering the brain and spinal cord tissue, thereby reducing inflammation and the resulting
821:
accompanying the drug will be updated to include this information. As of
February 2012, there were 212 confirmed cases of PML among 99,571 patients treated with natalizumab (2.1 cases per 1000 patients). All 54 patients with PML for whom samples were available before the diagnosis were positive for
1109:
may produce immunosuppression, and the
Tysabri prescribing information recommends that people taking corticosteroids for the treatment of Crohn's disease have their doses reduced before starting natalizumab treatment. The risk of developing PML was later estimated to be 1 in 1,000 (0.1%) over 18
1034:. In CD patients, sites of active inflammation of the bowel in CD patients have increased expression of addressin, suggesting a connection between the inflammation and the receptor. Natalizumab may block interaction between the α4β7 integrin and addressin at sites of inflammation.
791:
People with rapidly evolving severe relapsing remitting multiple sclerosis defined by two or more disabling relapses in one year, and with one or more
Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent
1175:
In 2007, the EMA rejected the application to market natalizumab for Crohn's disease due to concerns over its risk/benefit ratio. In
January 2008, the FDA approved it for the induction of remission and maintenance of remission for moderate to severe Crohn's disease.
809:, a viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of progressive multifocal leukoencephalopathy include the presence of anti-JCV antibodies (antibodies to the
817:
2010, the FDA noted a total of 31 confirmed cases of PML, with the chance of developing the infection increasing as the number of infusions received by a patient increased. Because of this association, the drug label and
756:, it has been approved only for multiple sclerosis and only by itself as the initial cases of PML, and later the fatalities, were said by the manufacturers to be linked to the use of previous medicines by the person.
2120:
Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, et al. (August 2011). "Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring".
3631:
769:
followed by periods of stability; and active secondary progressive disease – when, following a relapsing-remitting course, patients experience gradual disability worsening with continued relapses.
1022:(also known as MADCAM1) endothelial cell receptor is believed to contribute to the chronic bowel inflammation that causes Crohn's disease. Addressin is primarily expressed in the endothelium of
388:
2853:
3162:
1655:
3722:
2764:
Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, et al. (May 2007). "Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring".
1760:
5263:
3288:
2057:
848:
can appear as soon as six days after an initial dose; reactions are unpredictable and may appear even if the patient does not react to previous treatment. Such signs reoccur upon
3432:
343:
1385:
2954:
1686:
1094:
individuals or those with a history of PML. Due to the uncertain risk of PML, natalizumab is only available through a restricted distribution program. By
January 2010, the
1500:
652:
1105:
states that the drug has only been linked to PML when combined with other immune-modulating drugs and natalizumab is contraindicated for use with other immunomodulators.
3621:
35:
724:
The most common side effects are urinary tract infection, nasopharyngitis (inflammation of the nose and throat), headache, dizziness, nausea, joint pain and tiredness.
3717:
1185:
1155:
241:
3821:
2886:
5256:
3281:
3058:
1875:
Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di
Pietrantonj C, et al. (October 2011). "Natalizumab for relapsing remitting multiple sclerosis".
1717:
2053:
1228:
1095:
1051:
806:
732:
1648:"Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time"
2843:
3669:
1906:
1158:
recommended authorizing natalizumab to treat relapsing-remitting MS, and natalizumab was approved for medical use in the
European Union in June 2006.
168:
1417:
4737:
3773:
3306:
3154:
3131:
3196:
2015:
744:
its reintroduction by
October 2009, showing a sharp rise in the number of fatalities and prompting a review of the chemical for human use by the
2817:
2309:
788:
People with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT), or
5249:
3778:
3654:
3601:
3274:
3144:
Text was copied from this source which is copyright
European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1565:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
6272:
3788:
3593:
2352:
1907:"Annex: Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the member states"
1748:
1647:
956:
3005:
2372:
2172:
2049:
3753:
3679:
3639:
2965:
2202:
1575:
1074:
was reported in a patient being treated for Crohn's disease. Though the patient was being treated with natalizumab in combination with
895:
and exacerbation of Crohn's disease in a minority of patients with the condition. Adolescents with Crohn's disease experience headache,
2277:
1552:
1266:
1136:
1118:
Biogen Idec announced the initiation of the first clinical trial of natalizumab as a potential cancer treatment as of September 2008.
902:
About 6% of the people in studies developed long-lasting antibodies against natalizumab, which reduced the medicine's effectiveness.
4680:
4050:
849:
3712:
3095:
1377:
1147:
or second-line therapy. Patients taking natalizumab must enter into a registry for monitoring. Natalizumab is the only drug after
2511:"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis"
3814:
3783:
3659:
3649:
3606:
3460:
3427:
3407:
3748:
1678:
1492:
5089:
3380:
2050:"FDA Drug Safety Communication: Risk of Progressive Multifocal Leukoencephalopathy (PML) with the use of Tysabri (natalizumab)"
1447:
373:
273:
1296:
1003:
into the brain's parenchyma, and also reduced lesioning, though it is uncertain if this is clinically significant for humans.
6338:
6244:
3664:
3576:
2415:
Rice GP, Hartung HP, Calabresi PA (2005). "Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale".
1355:
96:
6254:
3886:
3743:
3707:
3402:
3190:
3091:
2882:
2288:
2198:
2021:
1754:
1625:
749:
543:
68:
1946:
292:
6343:
6289:
3995:
3807:
836:
or other evidence of significant liver damage. This rate is comparable to other immune-suppressing drugs. Evidence of
813:, a typically harmless virus carried by most humans), longer duration of therapy and prior use of immunosuppressants.
781:
603:
832:
injury, leading to the FDA, EMEA and manufacturers recommending that the medication be discontinued in patients with
6308:
3865:
2253:
999:
gene. In animals used to model MS and test therapies, repeated administration of natalizumab reduced migration of
825:
75:
5838:
4543:
3644:
3529:
3319:
3125:
3037:
2961:
2875:
2260:
2231:
1913:
1582:
1546:
1189:
745:
43:
3051:
6348:
4923:
1709:
1039:
935:, the first drug developed in the class of selective adhesion molecule inhibitors. α4-integrin is required for
143:
2224:
1221:
972:
714:
3030:
1101:
Though the small number of cases precludes conclusion on the ability of natalizumab alone to induce PML, its
748:. By 2010, 31 cases of PML were attributed to natalizumab while by 2018 this had risen to 757 cases. The US
82:
6277:
4918:
3364:
1055:
947:
is believed to be the prevention of immune cells from crossing blood vessel walls to reach affected organs.
728:
329:
54:
39:
1917:
4723:
4149:
3830:
3298:
1407:
980:
845:
740:
692:
592:
1319:"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)"
5350:
5272:
4910:
3120:
2460:"The monoclonal anti-VLA4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans"
1195:
In August 2023, the FDA approved approved Tyruko (natalizumab-sztn) and granted approval to Sandoz Inc.
928:
861:
64:
3266:
3184:
2991:"SOR/2008-101: Food and Drug Act; Regulations Amending the Food and Drug Regulations (1528—Schedule F)"
2305:
2027:
784:
in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:
5554:
3799:
3687:
3611:
3344:
2990:
2876:"Errata to FDA Background document for the Tysabri (natalizumab) Advisory Committee on July 31, 2007"
2807:
1318:
1144:
853:
469:
336:
2721:
Aksamit AJ (November 2006). "Review of progressive multifocal leukoencephalopathy and natalizumab".
852:
in some patients, indicating that damage is not coincidental. In the absence of any blockage these
619:
4131:
3515:
3437:
2337:
944:
699:
688:
487:
178:
161:
2079:
Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. (May 2012).
1440:"Tysabri 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC)"
5739:
5698:
5538:
5330:
5080:
4181:
3616:
3500:
3495:
3490:
3480:
2936:
2848:
2789:
2746:
2703:
2491:
2440:
2369:
2164:
2146:
1132:
1063:
925:
736:
685:
677:
303:
5120:
4978:
2593:"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy"
2194:
1031:
828:
in early 2008 revealed that 0.1% of people taking natalizumab experience clinically significant
681:
5130:
4816:
4257:
1586:
5630:
5300:
5241:
5085:
5075:
3876:
3834:
3692:
3475:
3385:
3255:
2928:
2781:
2738:
2695:
2660:
2622:
2573:
2532:
2483:
2432:
2397:
2138:
2102:
1996:
1888:
1857:
1801:
1165:
1102:
1091:
872:
413:
400:
213:
147:
1651:
5620:
5610:
4881:
4784:
4447:
4343:
3417:
3245:
3235:
2955:"European Medicines Agency: Committee for Medicinal Products for Human Use 24–27 April 2006"
2920:
2812:
2773:
2730:
2687:
2652:
2612:
2604:
2563:
2522:
2473:
2424:
2274:
2130:
2092:
1986:
1973:
Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. (July 2005).
1880:
1847:
1837:
1541:
1087:
1027:
936:
731:
by its manufacturer after it was linked with three cases of the rare neurological condition
496:
451:
3222:
Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, et al. (April 2017).
2591:
Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. (March 2006).
1258:
1050:
Natalizumab appears to interact with other immune-modulating drugs to increase the risk of
987:
on the surfaces of cells. The effect appears to occur on endothelial cells expressing the
727:
Natalizumab was approved for medical use in the United States in 2004. It was subsequently
552:
6322:
6038:
5814:
5180:
5065:
3727:
3697:
2464:
2376:
2292:
2281:
1975:"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease"
940:
459:
3087:
89:
623:
6283:
5070:
4938:
4586:
4420:
4399:
4395:
4391:
4019:
3856:
3702:
3392:
3354:
3250:
3223:
2734:
2617:
2592:
2428:
1852:
1825:
1140:
1106:
1079:
837:
818:
753:
752:(FDA) did not withdraw the drug from the market as benefits outweigh the risks. In the
2777:
2134:
6332:
6193:
5994:
5939:
5864:
5824:
5744:
5638:
5284:
5276:
5220:
5150:
5060:
4967:
4753:
4453:
4375:
4327:
4307:
4165:
4081:
3932:
3898:
3550:
2678:
Ransohoff RM (August 2007). ""Thinking without thinking" about natalizumab and PML".
2495:
1779:
1412:
1164:
added natalizumab to Schedule F of the Food and Drug Regulations in April 2008, as a
1161:
802:
706:
426:
265:
2940:
2793:
2750:
2707:
2444:
2225:"EMEA concludes new advice to doctors and patients for Tysabri (natalizumab) needed"
2150:
1439:
6183:
6168:
6148:
6138:
6117:
6033:
5974:
5959:
5929:
5909:
5904:
5879:
5859:
5854:
5849:
5799:
5789:
5779:
5729:
5724:
5719:
5648:
5533:
5517:
5420:
5410:
5405:
5380:
5320:
5230:
5190:
5175:
5170:
4886:
4836:
4831:
4811:
4691:
4686:
4549:
4534:
4482:
4458:
4405:
4282:
4272:
4091:
4008:
4003:
3961:
3914:
3871:
3838:
3510:
2656:
2165:"EMA confirms recommendations to minimise risk of brain infection PML with Tysabri"
1884:
1288:
1075:
1035:
968:
964:
703:
356:
351:
251:
2552:"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab"
2924:
2478:
2459:
1010:-expressing cells, with research suggesting a peak in expression after 72 hours.
6249:
6239:
6178:
6163:
6153:
6143:
6122:
6107:
6092:
6087:
6082:
6057:
6010:
5989:
5984:
5979:
5969:
5964:
5949:
5924:
5914:
5894:
5874:
5869:
5834:
5819:
5809:
5804:
5774:
5764:
5734:
5688:
5683:
5673:
5658:
5643:
5615:
5600:
5585:
5580:
5575:
5543:
5486:
5481:
5471:
5451:
5430:
5425:
5395:
5315:
5225:
5165:
5155:
5145:
5045:
5035:
5025:
5020:
4985:
4896:
4891:
4866:
4856:
4846:
4821:
4806:
4801:
4759:
4729:
4715:
4696:
4639:
4597:
4592:
4578:
4573:
4559:
4539:
4492:
4468:
4426:
4410:
4381:
4365:
4333:
4317:
4312:
4287:
4237:
4227:
4222:
4217:
4206:
4196:
4101:
4013:
3971:
3956:
3950:
3946:
3893:
3525:
3465:
2344:
1348:"Tysabri natalizumab 150 mg/1 mL injection solution pre-filled syringe (353845)"
1071:
996:
976:
892:
880:
774:
259:
1347:
137:
6209:
6188:
6173:
6158:
6102:
6097:
6077:
6072:
6043:
6017:
5954:
5934:
5919:
5899:
5889:
5844:
5794:
5784:
5759:
5754:
5749:
5714:
5709:
5678:
5663:
5605:
5595:
5590:
5570:
5507:
5502:
5491:
5461:
5456:
5400:
5375:
5360:
5345:
5340:
5310:
5215:
5210:
5195:
5135:
5125:
5110:
5105:
5100:
5050:
5040:
5030:
4995:
4973:
4959:
4871:
4861:
4851:
4841:
4826:
4769:
4764:
4743:
4658:
4653:
4611:
4605:
4506:
4463:
4359:
4349:
4302:
4292:
4267:
4262:
4252:
4247:
4242:
4232:
4191:
4176:
4171:
4155:
4096:
4076:
4025:
3985:
3966:
3908:
3569:
3505:
3485:
3470:
3444:
3329:
2691:
1842:
1083:
1042:
and the VCAM-1 gene may also play a part in CD but its role is not yet clear.
992:
640:
527:
231:
2285:
1617:
6112:
5944:
5769:
5668:
5653:
5512:
5476:
5466:
5440:
5435:
5415:
5390:
5385:
5370:
5365:
5335:
5305:
5205:
5200:
5185:
5160:
5115:
5095:
5055:
4990:
4954:
4876:
4672:
4625:
4554:
4520:
4487:
4297:
4277:
4186:
4086:
3926:
3545:
3540:
3349:
3334:
2306:"Multiple Sclerosis - Natalizumab (Tysabri) Can Rarely Cause Liver Problems"
1576:"Meeting highlights from the Committee for Medicinal Products for Human Use"
1169:
1148:
1019:
1000:
913:
841:
765:
710:
245:
183:
129:
3259:
2932:
2785:
2742:
2699:
2664:
2626:
2577:
2536:
2487:
2436:
2401:
2142:
2106:
2081:"Risk of natalizumab-associated progressive multifocal leukoencephalopathy"
2000:
1892:
1861:
1805:
1098:
reported a total of 31 confirmed cases of PML associated with natalizumab.
979:. Natalizumab appears to reduce the transmission of immune cells into the
2097:
2080:
2016:"Natalizumab Injection for Intraveneous {{sic}} Use (marketed as Tysabri)"
5522:
5445:
5355:
5325:
5140:
5015:
4704:
4212:
4122:
4058:
3980:
3535:
3324:
3240:
2608:
2568:
2551:
2527:
2510:
2458:
Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R (2008).
1991:
1974:
1826:"Natalizumab: A new treatment for relapsing remitting multiple sclerosis"
1621:
1059:
932:
918:
884:
833:
810:
507:
287:
201:
3155:"Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar"
2550:
Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (July 2005).
516:
5999:
5884:
4633:
3339:
2348:
1067:
1023:
876:
857:
195:
53:
if you can. Unsourced or poorly sourced material may be challenged and
151:
6224:
4948:
4779:
3314:
988:
960:
888:
583:
1792:"Natalizumab: new drug. Multiple sclerosis: risky market approval".
1026:
in the small intestine and are critical in guiding T-lymphocytes to
2338:"Important safety information: Dear Healthcare Practitioner letter"
572:
4647:
4500:
3088:"FDA Approves Tysabri to Treat Moderate-to-Severe Crohn's Disease"
1682:
1006:
Individuals with MS dosed with natalizumab demonstrated increased
984:
896:
865:
829:
695:
187:
1778:
This article incorporates text from this source, which is in the
1066:
developed PML. One died, and the other recovered with disabling
4619:
4567:
4528:
4514:
4068:
3942:
3359:
1007:
563:
435:
407:
5245:
3803:
3270:
420:
282:
16:
Medication used to treat multiple sclerosis and Crohn's disease
4476:
3115:
3113:
1326:
1062:. In 2005, two people taking natalizumab in combination with
18:
1618:"PML Risk Increases With Repeated Natalizumab Infusions: FDA"
1151:
withdrawn for safety reasons that returned to the US market.
608:
1749:"FDA Approves First Biosimilar to Treat Multiple Sclerosis"
1378:"Tysabri Product and Consumer Medicine Information Licence"
1038:
have found higher levels of VCAM-1 expression in mice with
382:
314:
3723:
Megalencephalic leukoencephalopathy with subcortical cysts
1222:"Tyruko (natalizumab-sztn) injection, for intravenous use"
801:
The US prescribing information for natalizumab contains a
780:
In the European Union, natalizumab is indicated as single
702:. The drug is believed to work by reducing the ability of
3224:"Natalizumab in Multiple Sclerosis: Long-Term Management"
709:
to attach to and pass through the cell layers lining the
1110:
months though the longer term risks of PML are unknown.
395:
2844:"F.D.A. Panel Recommends M.S. Drug Despite Lethal Risk"
659:
50:
2911:
Fiore D (2007). "Multiple sclerosis and Natalizumab".
1947:"Biogen, Elan Report Brain Illness in Tysabri Patient"
6306:
3433:
Lesional demyelinations of the central nervous system
1940:
1938:
1131:
Natalizumab was originally approved for treatment of
1487:
1485:
856:
are predictors of severe liver injury with possible
6232:
6222:
6202:
6131:
6065:
6056:
6025:
5697:
5629:
5563:
5292:
5283:
5008:
4936:
4909:
4794:
4437:
4139:
4130:
4121:
4114:
4067:
4049:
4040:
3994:
3925:
3855:
3846:
3766:
3736:
3678:
3630:
3592:
3585:
3559:
3453:
3373:
3305:
2808:"Biogen Idec testing Tysabri as a cancer treatment"
2254:"Questions and answers on Tysabri and liver injury"
1483:
1481:
1479:
1477:
1475:
1473:
1471:
1469:
1467:
1465:
639:
634:
602:
582:
562:
542:
526:
506:
486:
481:
468:
458:
450:
372:
367:
342:
328:
302:
272:
258:
240:
230:
222:
212:
207:
194:
177:
167:
160:
1743:
1741:
1739:
1737:
1735:
1216:
1214:
1212:
1210:
1208:
3622:Chronic inflammatory demyelinating polyneuropathy
2509:Kleinschmidt-DeMasters BK, Tyler KL (July 2005).
2014:U.S. Food and Drug Administration (August 2008).
3031:"Refusal CHMP assessment report for natalizumab"
1070:. A third fatal case initially attributed to an
773:existing medications. Natalizumab is used as a
3718:Leukoencephalopathy with vanishing white matter
2638:
2636:
2195:"FDA MedWatch - 2008 Safety Information Alerts"
1968:
1966:
1964:
1819:
1817:
1815:
1536:
1534:
1532:
1530:
1528:
1526:
1524:
1522:
1520:
1518:
495:
146:bound to the headpiece of an α4-integrin. From
1186:Committee for Medicinal Products for Human Use
1156:Committee for Medicinal Products for Human Use
49:Please review the contents of the article and
5257:
3815:
3282:
1253:
1251:
1249:
1018:The interaction of the α4β7 integrin and the
8:
1289:"Natalizumab (Tysabri) Use During Pregnancy"
735:(PML) when administered in combination with
676:among others, is a medication used to treat
291:
128:
1877:The Cochrane Database of Systematic Reviews
1611:
1609:
1607:
443:In general: ℞ (Prescription only)
6229:
6062:
5289:
5264:
5250:
5242:
4136:
4127:
4118:
4046:
3852:
3822:
3808:
3800:
3589:
3289:
3275:
3267:
2388:Horga A, Horga de la Parte JF (2007). "".
1710:"Tysabri safety falls under EMEA scrutiny"
1096:United States Food and Drug Administration
1052:progressive multifocal leukoencephalopathy
975:through interaction with receptors on the
807:progressive multifocal leukoencephalopathy
733:progressive multifocal leukoencephalopathy
622:
136:
3670:Experimental autoimmune encephalomyelitis
3249:
3239:
2643:Berger JR (October 2006). "Natalizumab".
2616:
2567:
2526:
2477:
2096:
1990:
1851:
1841:
1830:Therapeutics and Clinical Risk Management
1679:"MS Drug Tysabri Tied to Brain Infection"
1139:, due to the drug's efficacy in one-year
551:
3774:List of multiple sclerosis organizations
2336:Panzara M, Francis V (1 February 2008).
912:
840:in the form of elevated blood levels of
6313:
1204:
1135:in 2004, through the FDA's accelerated
618:
515:
264:
3779:List of people with multiple sclerosis
3655:Neuromyelitis optica spectrum disorder
3602:Neuromyelitis optica spectrum disorder
2837:
2835:
2331:
2329:
2327:
1352:Therapeutic Goods Administration (TGA)
127:
1689:from the original on 20 November 2018
1299:from the original on 23 November 2020
963:of MS are believed to be caused when
899:and exacerbation of Crohn's disease.
764:In the United states, natalizumab is
591:
250:
7:
3754:Mitochondrial DNA depletion syndrome
3640:Acute disseminated encephalomyelitis
2856:from the original on 11 January 2016
2820:from the original on 29 October 2013
2680:Journal of the Neurological Sciences
2312:from the original on 7 November 2016
2175:from the original on 23 January 2021
1720:from the original on 23 January 2021
1628:from the original on 26 January 2012
1450:from the original on 22 October 2020
1269:from the original on 28 October 2023
355:
3199:from the original on 28 August 2021
3134:from the original on 25 August 2023
3011:from the original on 18 August 2011
2597:The New England Journal of Medicine
2556:The New England Journal of Medicine
2515:The New England Journal of Medicine
2085:The New England Journal of Medicine
1979:The New England Journal of Medicine
1763:from the original on 25 August 2023
1420:from the original on 25 August 2023
1358:from the original on 25 August 2023
1234:from the original on 25 August 2023
571:
2735:10.1097/01.nrl.0000250948.04681.96
2429:10.1212/01.WNL.0000158329.30470.D0
2060:from the original on 24 April 2019
1555:from the original on 6 August 2020
1503:from the original on 27 March 2020
14:
3165:from the original on 24 July 2023
3064:from the original on 18 July 2009
2971:from the original on 10 July 2007
1759:(Press release). 24 August 2023.
1654:. 10 October 2018. Archived from
1585:. 22 October 2009. Archived from
6316:
3784:Multiple sclerosis drug pipeline
3660:Diffuse myelinoclastic sclerosis
3650:Marburg acute multiple sclerosis
3607:Diffuse myelinoclastic sclerosis
3461:Management of multiple sclerosis
3428:Radiologically isolated syndrome
3408:Expanded Disability Status Scale
3098:from the original on 23 May 2009
2913:American Journal of Therapeutics
2892:from the original on 17 May 2017
2358:from the original on 12 May 2009
2205:from the original on 25 May 2009
1773:
1493:"Tysabri- natalizumab injection"
1388:from the original on 3 July 2022
985:α4β7-integrin receptor molecules
115:
23:
3381:Diagnosis of multiple sclerosis
871:Common adverse effects include
3665:Tumefactive multiple sclerosis
3577:Research in multiple sclerosis
3297:Demyelinating diseases of the
2657:10.1358/dot.2006.42.10.1042190
1945:Greene RT (15 December 2008).
1885:10.1002/14651858.CD007621.pub2
51:add the appropriate references
1:
3185:"Biosimilar Drug Information"
3121:"Tyruko: Pending EC decision"
2778:10.1016/S1474-4422(07)70078-9
2135:10.1016/S1474-4422(11)70149-1
1616:Jeffrey S (5 February 2010).
1408:"Tysabri Product information"
3887:dihydroorotate dehydrogenase
3744:Central pontine myelinolysis
3713:Pelizaeus–Merzbacher disease
3708:Metachromatic leukodystrophy
3403:Clinically isolated syndrome
3374:Investigations and diagnosis
3191:Food and Drug Administration
3092:Food and Drug Administration
2925:10.1097/MJT.0b013e31804bfa6a
2883:Food and Drug Administration
2479:10.1182/blood-2007-10-120329
2199:Food and Drug Administration
2022:Food and Drug Administration
1755:Food and Drug Administration
1708:Staton T (26 October 2009).
805:about the increased risk of
750:Food and Drug Administration
672:, sold under the brand name
3866:purine synthesis inhibitors
3749:Marchiafava–Bignami disease
1800:(93): 7–10. February 2008.
1168:requiring oversight from a
36:reliable medical references
6365:
1824:Hutchinson M (June 2007).
826:Postmarketing surveillance
635:Chemical and physical data
6267:
4051:IL-1 receptor antagonists
3645:Balo concentric sclerosis
3126:European Medicines Agency
3038:European Medicines Agency
3004:(8): 649. 16 April 2008.
2962:European Medicines Agency
2692:10.1016/j.jns.2006.04.011
2261:European Medicines Agency
2232:European Medicines Agency
2201:(FDA). 28 February 2008.
2169:European Medicines Agency
1914:European Medicines Agency
1843:10.2147/tcrm.2007.3.2.259
1677:Hitti M (1 August 2008).
1583:European Medicines Agency
1547:European Medicines Agency
1263:European Medicines Agency
1190:European Medicines Agency
782:disease modifying therapy
746:European Medicines Agency
729:withdrawn from the market
649:
135:
42:or relies too heavily on
4924:Anti-lymphocyte globulin
3094:(FDA). 14 January 2008.
2842:Pollack (9 March 2006).
2304:Gross K (3 March 2008).
1040:irritable bowel syndrome
983:by interfering with the
236:natalizumab-sztn, Tyruko
4919:Anti-thymocyte globulin
3831:Immunosuppressive drugs
2291:5 December 2008 at the
1794:Prescrire International
1056:opportunistic infection
1013:
917:Structure of a generic
4724:Interleukin-6 receptor
4150:Complement component 5
3586:Demyelinating diseases
3299:central nervous system
2964:(EMA). 28 April 2006.
1054:(PML), an often-fatal
981:central nervous system
921:
741:immunosuppressive drug
693:cell adhesion molecule
6339:Monoclonal antibodies
5351:Camidanlumab tesirine
5273:Monoclonal antibodies
2998:Canada Gazette Part I
2885:(FDA). 20 July 2007.
2766:The Lancet. Neurology
2098:10.1056/NEJMoa1107829
1551:. 17 September 2018.
1295:. 24 September 2019.
1265:. 28 September 2023.
995:cells expressing the
931:against alpha-4 (α4)
916:
862:liver transplantation
6026:Chimeric + humanized
5555:Nivolumab/relatlimab
3688:Adrenoleukodystrophy
3612:MOG antibody disease
3414:Serological and CSF
3365:Uhthoff's phenomenon
3241:10.3390/ijms18050940
2816:. 5 September 2008.
2609:10.1056/NEJMoa054693
2569:10.1056/NEJMoa051847
2528:10.1056/NEJMoa051782
2375:11 June 2008 at the
2280:11 June 2008 at the
1992:10.1056/NEJMoa051586
1446:. 14 November 2019.
943:, and natalizumab's
854:liver function tests
700:intravenous infusion
3516:Monomethyl fumarate
3195:. 1 November 2023.
2030:on 19 December 2008
1592:on 27 December 2009
1416:. 22 October 2009.
1154:In April 2006, the
1122:Society and culture
973:blood–brain barrier
945:mechanism of action
929:monoclonal antibody
909:Mechanism of action
879:with a low risk of
715:blood–brain barrier
689:monoclonal antibody
416:(Prescription only)
391:(Prescription only)
226:AN100226M, Antegren
162:Monoclonal antibody
132:
6344:Immunosuppressants
6294:Never to phase III
5740:Certolizumab pegol
5707:Immunosuppressive:
5081:Diroximel fumarate
4754:IL-2 receptor/CD25
4182:Certolizumab pegol
3835:Immunosuppressants
3617:Multiple sclerosis
3501:Interferon beta-1b
3496:Interferon beta-1a
3491:Glatiramer acetate
3481:Diroximel fumarate
3454:Approved treatment
3307:Signs and symptoms
3040:. 15 November 2007
2849:The New York Times
1658:on 28 October 2021
1499:. 12 August 2019.
1354:. 12 August 2022.
1184:In July 2023, the
1137:Fast Track program
1133:multiple sclerosis
1064:interferon beta-1a
951:Multiple sclerosis
924:Natalizumab is a
922:
877:allergic reactions
737:interferon beta-1a
678:multiple sclerosis
6304:
6303:
6263:
6262:
6218:
6217:
6052:
6051:
6007:Immune activation
5499:Immune activation
5301:Immunosuppression
5239:
5238:
5086:Efgartigimod alfa
5076:Dimethyl fumarate
5004:
5003:
4932:
4931:
4905:
4904:
4110:
4109:
4036:
4035:
3877:Mycophenolic acid
3797:
3796:
3762:
3761:
3693:Alexander disease
3476:Dimethyl fumarate
3418:Oligoclonal bands
3386:McDonald criteria
2960:(Press release).
2171:. 25 April 2016.
2091:(20): 1870–1880.
1923:on 20 August 2007
1166:prescription drug
1103:black box warning
1028:lymphatic tissues
977:endothelial cells
971:pass through the
937:white blood cells
698:. It is given by
667:
666:
604:CompTox Dashboard
439:
424:
411:
398:
386:
318:
285:
124:
123:
100:
6356:
6321:
6320:
6319:
6312:
6230:
6063:
5621:Zolimomab aritox
5611:Telimomab aritox
5290:
5266:
5259:
5252:
5243:
4882:Telimomab aritox
4785:Zolimomab aritox
4606:CD62L/L-selectin
4344:Immunoglobulin E
4137:
4128:
4119:
4047:
3853:
3824:
3817:
3810:
3801:
3590:
3560:Other treatments
3438:Dawson's fingers
3291:
3284:
3277:
3268:
3263:
3253:
3243:
3209:
3208:
3206:
3204:
3181:
3175:
3174:
3172:
3170:
3161:. 24 July 2023.
3151:
3145:
3143:
3141:
3139:
3130:. 21 July 2023.
3117:
3108:
3107:
3105:
3103:
3084:
3078:
3077:
3073:
3071:
3069:
3063:
3056:
3049:
3047:
3045:
3035:
3027:
3021:
3020:
3018:
3016:
3010:
2995:
2987:
2981:
2980:
2978:
2976:
2970:
2959:
2951:
2945:
2944:
2908:
2902:
2901:
2899:
2897:
2891:
2880:
2872:
2866:
2865:
2863:
2861:
2839:
2830:
2829:
2827:
2825:
2813:The Boston Globe
2804:
2798:
2797:
2761:
2755:
2754:
2718:
2712:
2711:
2675:
2669:
2668:
2640:
2631:
2630:
2620:
2588:
2582:
2581:
2571:
2547:
2541:
2540:
2530:
2506:
2500:
2499:
2481:
2455:
2449:
2448:
2412:
2406:
2405:
2385:
2379:
2367:
2365:
2363:
2357:
2342:
2333:
2322:
2321:
2319:
2317:
2301:
2295:
2272:
2270:
2268:
2258:
2250:
2244:
2243:
2241:
2239:
2229:
2221:
2215:
2214:
2212:
2210:
2191:
2185:
2184:
2182:
2180:
2161:
2155:
2154:
2123:Lancet Neurology
2117:
2111:
2110:
2100:
2076:
2070:
2069:
2067:
2065:
2046:
2040:
2039:
2037:
2035:
2026:. Archived from
2011:
2005:
2004:
1994:
1970:
1959:
1958:
1956:
1954:
1942:
1933:
1932:
1930:
1928:
1922:
1916:. Archived from
1911:
1903:
1897:
1896:
1879:(10): CD007621.
1872:
1866:
1865:
1855:
1845:
1821:
1810:
1809:
1789:
1783:
1777:
1776:
1772:
1770:
1768:
1745:
1730:
1729:
1727:
1725:
1705:
1699:
1698:
1696:
1694:
1674:
1668:
1667:
1665:
1663:
1644:
1638:
1637:
1635:
1633:
1613:
1602:
1601:
1599:
1597:
1591:
1580:
1572:
1566:
1564:
1562:
1560:
1538:
1513:
1512:
1510:
1508:
1489:
1460:
1459:
1457:
1455:
1436:
1430:
1429:
1427:
1425:
1404:
1398:
1397:
1395:
1393:
1374:
1368:
1367:
1365:
1363:
1344:
1338:
1337:
1335:
1333:
1323:nctr-crs.fda.gov
1315:
1309:
1308:
1306:
1304:
1285:
1279:
1278:
1276:
1274:
1255:
1244:
1243:
1241:
1239:
1233:
1226:
1218:
1092:immunosuppressed
663:
662:
655:
627:
626:
612:
610:
595:
575:
555:
519:
499:
473:
437:
434:
429:
422:
419:
409:
406:
403: Schedule D
397:
394:
384:
381:
359:
316:
313:
295:
284:
281:
268:
254:
154:
140:
133:
131:
119:
118:
110:
107:
101:
99:
58:
27:
26:
19:
6364:
6363:
6359:
6358:
6357:
6355:
6354:
6353:
6349:Withdrawn drugs
6329:
6328:
6327:
6317:
6315:
6307:
6305:
6300:
6299:
6284:Clinical trials
6259:
6214:
6198:
6127:
6048:
6039:Rozanolixizumab
6027:
6021:
6013:
6002:
5815:Lulizumab pegol
5693:
5625:
5559:
5279:
5270:
5240:
5235:
5181:Rozanolixizumab
5066:Deucravacitinib
5000:
4928:
4901:
4790:
4439:
4433:
4141:
4106:
4063:
4042:
4032:
3990:
3930:
3921:
3857:Antimetabolites
3848:
3842:
3828:
3798:
3793:
3789:Pathophysiology
3758:
3732:
3728:CAMFAK syndrome
3698:Canavan disease
3674:
3626:
3581:
3555:
3449:
3369:
3301:
3295:
3221:
3218:
3216:Further reading
3213:
3212:
3202:
3200:
3183:
3182:
3178:
3168:
3166:
3153:
3152:
3148:
3137:
3135:
3119:
3118:
3111:
3101:
3099:
3086:
3085:
3081:
3075:
3067:
3065:
3061:
3054:
3050:
3043:
3041:
3033:
3029:
3028:
3024:
3014:
3012:
3008:
2993:
2989:
2988:
2984:
2974:
2972:
2968:
2957:
2953:
2952:
2948:
2910:
2909:
2905:
2895:
2893:
2889:
2878:
2874:
2873:
2869:
2859:
2857:
2841:
2840:
2833:
2823:
2821:
2806:
2805:
2801:
2763:
2762:
2758:
2723:The Neurologist
2720:
2719:
2715:
2677:
2676:
2672:
2651:(10): 639–655.
2642:
2641:
2634:
2590:
2589:
2585:
2549:
2548:
2544:
2508:
2507:
2503:
2457:
2456:
2452:
2414:
2413:
2409:
2387:
2386:
2382:
2377:Wayback Machine
2361:
2359:
2355:
2340:
2335:
2334:
2325:
2315:
2313:
2303:
2302:
2298:
2293:Wayback Machine
2282:Wayback Machine
2266:
2264:
2263:. 20 March 2008
2256:
2252:
2251:
2247:
2237:
2235:
2234:. 20 March 2008
2227:
2223:
2222:
2218:
2208:
2206:
2193:
2192:
2188:
2178:
2176:
2163:
2162:
2158:
2119:
2118:
2114:
2078:
2077:
2073:
2063:
2061:
2048:
2047:
2043:
2033:
2031:
2013:
2012:
2008:
1972:
1971:
1962:
1952:
1950:
1949:. Bloomberg.com
1944:
1943:
1936:
1926:
1924:
1920:
1909:
1905:
1904:
1900:
1874:
1873:
1869:
1823:
1822:
1813:
1791:
1790:
1786:
1774:
1766:
1764:
1747:
1746:
1733:
1723:
1721:
1707:
1706:
1702:
1692:
1690:
1676:
1675:
1671:
1661:
1659:
1646:
1645:
1641:
1631:
1629:
1615:
1614:
1605:
1595:
1593:
1589:
1578:
1574:
1573:
1569:
1558:
1556:
1540:
1539:
1516:
1506:
1504:
1491:
1490:
1463:
1453:
1451:
1438:
1437:
1433:
1423:
1421:
1406:
1405:
1401:
1391:
1389:
1376:
1375:
1371:
1361:
1359:
1346:
1345:
1341:
1331:
1329:
1317:
1316:
1312:
1302:
1300:
1287:
1286:
1282:
1272:
1270:
1257:
1256:
1247:
1237:
1235:
1231:
1224:
1220:
1219:
1206:
1201:
1182:
1141:clinical trials
1129:
1124:
1116:
1107:Corticosteroids
1088:contraindicated
1080:corticosteroids
1048:
1032:Peyer's patches
1016:
1014:Crohn's disease
953:
911:
905:
799:
797:Adverse effects
762:
682:Crohn's disease
658:
656:
653:(what is this?)
650:
645:149 kg/mol
630:
606:
598:
578:
558:
538:
522:
502:
471:
460:Bioavailability
452:Pharmacokinetic
446:
427:
363:
331:
324:
305:
298:
218:Tysabri, others
156:
150:
120:
116:
111:
105:
102:
59:
48:
44:primary sources
28:
24:
17:
12:
11:
5:
6362:
6360:
6352:
6351:
6346:
6341:
6331:
6330:
6326:
6325:
6302:
6301:
6298:
6297:
6296:
6295:
6292:
6281:
6275:
6269:
6268:
6265:
6264:
6261:
6260:
6258:
6257:
6252:
6247:
6242:
6236:
6234:
6227:
6220:
6219:
6216:
6215:
6213:
6212:
6206:
6204:
6200:
6199:
6197:
6196:
6191:
6186:
6181:
6176:
6171:
6166:
6161:
6156:
6151:
6146:
6141:
6135:
6133:
6129:
6128:
6126:
6125:
6120:
6115:
6110:
6105:
6100:
6095:
6090:
6085:
6080:
6075:
6069:
6067:
6060:
6054:
6053:
6050:
6049:
6047:
6046:
6041:
6036:
6030:
6028:
6023:
6022:
6004:
6003:
5997:
5992:
5987:
5982:
5977:
5972:
5967:
5962:
5957:
5952:
5947:
5942:
5937:
5932:
5927:
5922:
5917:
5912:
5907:
5902:
5897:
5892:
5887:
5882:
5877:
5872:
5867:
5862:
5857:
5852:
5847:
5842:
5839:+hyaluronidase
5832:
5827:
5822:
5817:
5812:
5807:
5802:
5797:
5792:
5787:
5782:
5777:
5772:
5767:
5762:
5757:
5752:
5747:
5742:
5737:
5732:
5727:
5722:
5717:
5712:
5703:
5701:
5695:
5694:
5692:
5691:
5686:
5681:
5676:
5671:
5666:
5661:
5656:
5651:
5646:
5641:
5635:
5633:
5627:
5626:
5624:
5623:
5618:
5613:
5608:
5603:
5598:
5593:
5588:
5583:
5578:
5573:
5567:
5565:
5561:
5560:
5558:
5557:
5547:
5546:
5541:
5536:
5526:
5525:
5520:
5515:
5510:
5505:
5495:
5494:
5489:
5484:
5479:
5474:
5469:
5464:
5459:
5454:
5449:
5443:
5438:
5433:
5428:
5423:
5418:
5413:
5408:
5403:
5398:
5393:
5388:
5383:
5378:
5373:
5368:
5363:
5358:
5353:
5348:
5343:
5338:
5333:
5328:
5323:
5318:
5313:
5308:
5296:
5294:
5287:
5281:
5280:
5271:
5269:
5268:
5261:
5254:
5246:
5237:
5236:
5234:
5233:
5228:
5223:
5218:
5213:
5208:
5203:
5198:
5193:
5188:
5183:
5178:
5173:
5168:
5163:
5158:
5153:
5148:
5143:
5138:
5133:
5128:
5123:
5118:
5113:
5108:
5103:
5098:
5093:
5090:+hyaluronidase
5083:
5078:
5073:
5071:Deuruxolitinib
5068:
5063:
5058:
5053:
5048:
5043:
5038:
5033:
5028:
5023:
5018:
5012:
5010:
5006:
5005:
5002:
5001:
4999:
4998:
4993:
4988:
4983:
4982:
4981:
4976:
4964:
4963:
4962:
4957:
4944:
4942:
4934:
4933:
4930:
4929:
4927:
4926:
4921:
4915:
4913:
4907:
4906:
4903:
4902:
4900:
4899:
4894:
4889:
4884:
4879:
4874:
4869:
4864:
4859:
4854:
4849:
4844:
4839:
4834:
4829:
4824:
4819:
4814:
4809:
4804:
4798:
4796:
4792:
4791:
4789:
4788:
4775:
4774:
4773:
4772:
4767:
4762:
4749:
4748:
4747:
4746:
4734:
4733:
4732:
4720:
4719:
4718:
4713:
4701:
4700:
4699:
4694:
4689:
4677:
4676:
4675:
4664:
4663:
4662:
4661:
4656:
4644:
4643:
4642:
4630:
4629:
4628:
4616:
4615:
4614:
4602:
4601:
4600:
4595:
4583:
4582:
4581:
4576:
4564:
4563:
4562:
4557:
4552:
4547:
4544:+hyaluronidase
4537:
4525:
4524:
4523:
4511:
4510:
4509:
4497:
4496:
4495:
4490:
4485:
4473:
4472:
4471:
4466:
4461:
4456:
4443:
4441:
4435:
4434:
4432:
4431:
4430:
4429:
4416:
4415:
4414:
4413:
4408:
4387:
4386:
4385:
4384:
4371:
4370:
4369:
4368:
4355:
4354:
4353:
4352:
4339:
4338:
4337:
4336:
4323:
4322:
4321:
4320:
4315:
4310:
4305:
4300:
4295:
4290:
4285:
4280:
4275:
4270:
4265:
4260:
4255:
4250:
4245:
4240:
4235:
4230:
4225:
4220:
4215:
4202:
4201:
4200:
4199:
4194:
4189:
4184:
4179:
4174:
4161:
4160:
4159:
4158:
4145:
4143:
4134:
4125:
4116:
4112:
4111:
4108:
4107:
4105:
4104:
4099:
4094:
4089:
4084:
4079:
4073:
4071:
4065:
4064:
4062:
4061:
4055:
4053:
4044:
4038:
4037:
4034:
4033:
4031:
4030:
4029:
4028:
4020:PDE4 inhibitor
4016:
4011:
4006:
4000:
3998:
3992:
3991:
3989:
3988:
3983:
3977:
3976:
3975:
3974:
3969:
3964:
3959:
3938:
3936:
3923:
3922:
3920:
3919:
3918:
3917:
3904:
3903:
3902:
3901:
3896:
3882:
3881:
3880:
3879:
3874:
3861:
3859:
3850:
3844:
3843:
3829:
3827:
3826:
3819:
3812:
3804:
3795:
3794:
3792:
3791:
3786:
3781:
3776:
3770:
3768:
3764:
3763:
3760:
3759:
3757:
3756:
3751:
3746:
3740:
3738:
3734:
3733:
3731:
3730:
3725:
3720:
3715:
3710:
3705:
3703:Krabbe disease
3700:
3695:
3690:
3684:
3682:
3676:
3675:
3673:
3672:
3667:
3662:
3657:
3652:
3647:
3642:
3636:
3634:
3628:
3627:
3625:
3624:
3619:
3614:
3609:
3604:
3598:
3596:
3587:
3583:
3582:
3580:
3579:
3574:
3573:
3572:
3563:
3561:
3557:
3556:
3554:
3553:
3548:
3543:
3538:
3533:
3530:+hyaluronidase
3523:
3518:
3513:
3508:
3503:
3498:
3493:
3488:
3483:
3478:
3473:
3468:
3463:
3457:
3455:
3451:
3450:
3448:
3447:
3442:
3441:
3440:
3435:
3430:
3422:
3421:
3420:
3412:
3411:
3410:
3405:
3396:
3395:
3393:Poser criteria
3390:
3389:
3388:
3377:
3375:
3371:
3370:
3368:
3367:
3362:
3357:
3355:Optic neuritis
3352:
3347:
3342:
3337:
3332:
3327:
3322:
3317:
3311:
3309:
3303:
3302:
3296:
3294:
3293:
3286:
3279:
3271:
3265:
3264:
3217:
3214:
3211:
3210:
3176:
3146:
3109:
3079:
3076:(78.5 KB)
3022:
2982:
2946:
2919:(6): 555–560.
2903:
2867:
2831:
2799:
2772:(5): 431–441.
2756:
2729:(6): 293–298.
2713:
2686:(1–2): 50–52.
2670:
2645:Drugs of Today
2632:
2603:(9): 924–933.
2583:
2562:(4): 375–381.
2542:
2521:(4): 369–374.
2501:
2450:
2423:(8): 1336–42.
2407:
2396:(5): 293–303.
2392:(in Spanish).
2380:
2323:
2296:
2286:second summary
2245:
2216:
2186:
2156:
2112:
2071:
2056:. 2 May 2010.
2041:
2006:
1985:(4): 362–368.
1960:
1934:
1898:
1867:
1836:(2): 259–268.
1811:
1784:
1731:
1700:
1669:
1639:
1603:
1567:
1542:"Tysabri EPAR"
1514:
1461:
1431:
1399:
1369:
1339:
1310:
1280:
1245:
1203:
1202:
1200:
1197:
1188:(CHMP) of the
1181:
1178:
1128:
1125:
1123:
1120:
1115:
1112:
1058:caused by the
1047:
1044:
1015:
1012:
967:cells such as
952:
949:
910:
907:
838:hepatotoxicity
819:package insert
798:
795:
794:
793:
789:
761:
758:
754:European Union
721:nerve damage.
665:
664:
647:
646:
643:
637:
636:
632:
631:
629:
628:
620:DTXSID90920506
615:
613:
600:
599:
597:
596:
588:
586:
580:
579:
577:
576:
568:
566:
560:
559:
557:
556:
548:
546:
540:
539:
537:
536:
532:
530:
524:
523:
521:
520:
512:
510:
504:
503:
501:
500:
492:
490:
484:
483:
479:
478:
475:
466:
465:
462:
456:
455:
448:
447:
445:
444:
441:
432:
417:
404:
392:
378:
376:
370:
369:
365:
364:
362:
361:
348:
346:
340:
339:
334:
332:administration
326:
325:
323:
322:
320:
310:
308:
300:
299:
297:
296:
278:
276:
270:
269:
262:
256:
255:
248:
238:
237:
234:
228:
227:
224:
220:
219:
216:
210:
209:
205:
204:
198:
192:
191:
181:
175:
174:
173:Whole antibody
171:
165:
164:
158:
157:
141:
122:
121:
114:
112:
31:
29:
22:
15:
13:
10:
9:
6:
4:
3:
2:
6361:
6350:
6347:
6345:
6342:
6340:
6337:
6336:
6334:
6324:
6314:
6310:
6293:
6291:
6288:
6287:
6285:
6282:
6279:
6276:
6274:
6271:
6270:
6266:
6256:
6253:
6251:
6248:
6246:
6243:
6241:
6238:
6237:
6235:
6231:
6228:
6226:
6223:Inflammatory
6221:
6211:
6208:
6207:
6205:
6201:
6195:
6194:Tildrakizumab
6192:
6190:
6187:
6185:
6182:
6180:
6177:
6175:
6172:
6170:
6167:
6165:
6162:
6160:
6157:
6155:
6152:
6150:
6147:
6145:
6142:
6140:
6137:
6136:
6134:
6130:
6124:
6121:
6119:
6116:
6114:
6111:
6109:
6106:
6104:
6101:
6099:
6096:
6094:
6091:
6089:
6086:
6084:
6081:
6079:
6076:
6074:
6071:
6070:
6068:
6064:
6061:
6059:
6055:
6045:
6042:
6040:
6037:
6035:
6032:
6031:
6029:
6024:
6020:
6019:
6016:
6012:
6008:
6001:
5998:
5996:
5995:Vobarilizumab
5993:
5991:
5988:
5986:
5983:
5981:
5978:
5976:
5973:
5971:
5968:
5966:
5963:
5961:
5958:
5956:
5953:
5951:
5948:
5946:
5943:
5941:
5940:Spartalizumab
5938:
5936:
5933:
5931:
5928:
5926:
5923:
5921:
5918:
5916:
5913:
5911:
5908:
5906:
5903:
5901:
5898:
5896:
5893:
5891:
5888:
5886:
5883:
5881:
5878:
5876:
5873:
5871:
5868:
5866:
5865:Pembrolizumab
5863:
5861:
5858:
5856:
5853:
5851:
5848:
5846:
5843:
5840:
5836:
5833:
5831:
5828:
5826:
5825:Mogamulizumab
5823:
5821:
5818:
5816:
5813:
5811:
5808:
5806:
5803:
5801:
5798:
5796:
5793:
5791:
5788:
5786:
5783:
5781:
5778:
5776:
5773:
5771:
5768:
5766:
5763:
5761:
5758:
5756:
5753:
5751:
5748:
5746:
5745:Crizanlizumab
5743:
5741:
5738:
5736:
5733:
5731:
5728:
5726:
5723:
5721:
5718:
5716:
5713:
5711:
5708:
5705:
5704:
5702:
5700:
5696:
5690:
5687:
5685:
5682:
5680:
5677:
5675:
5672:
5670:
5667:
5665:
5662:
5660:
5657:
5655:
5652:
5650:
5647:
5645:
5642:
5640:
5639:Andecaliximab
5637:
5636:
5634:
5632:
5628:
5622:
5619:
5617:
5614:
5612:
5609:
5607:
5604:
5602:
5599:
5597:
5594:
5592:
5589:
5587:
5584:
5582:
5579:
5577:
5574:
5572:
5569:
5568:
5566:
5562:
5556:
5552:
5549:
5548:
5545:
5542:
5540:
5537:
5535:
5531:
5528:
5527:
5524:
5521:
5519:
5516:
5514:
5511:
5509:
5506:
5504:
5500:
5497:
5496:
5493:
5490:
5488:
5485:
5483:
5480:
5478:
5475:
5473:
5470:
5468:
5465:
5463:
5460:
5458:
5455:
5453:
5450:
5447:
5444:
5442:
5439:
5437:
5434:
5432:
5429:
5427:
5424:
5422:
5419:
5417:
5414:
5412:
5409:
5407:
5404:
5402:
5399:
5397:
5394:
5392:
5389:
5387:
5384:
5382:
5379:
5377:
5374:
5372:
5369:
5367:
5364:
5362:
5359:
5357:
5354:
5352:
5349:
5347:
5344:
5342:
5339:
5337:
5334:
5332:
5329:
5327:
5324:
5322:
5319:
5317:
5314:
5312:
5309:
5307:
5303:
5302:
5298:
5297:
5295:
5291:
5288:
5286:
5285:Immune system
5282:
5278:
5277:immune system
5274:
5267:
5262:
5260:
5255:
5253:
5248:
5247:
5244:
5232:
5229:
5227:
5224:
5222:
5221:Tildrakizumab
5219:
5217:
5214:
5212:
5209:
5207:
5204:
5202:
5199:
5197:
5194:
5192:
5189:
5187:
5184:
5182:
5179:
5177:
5174:
5172:
5169:
5167:
5164:
5162:
5159:
5157:
5154:
5152:
5151:Pegcetacoplan
5149:
5147:
5144:
5142:
5139:
5137:
5134:
5132:
5129:
5127:
5124:
5122:
5119:
5117:
5114:
5112:
5109:
5107:
5104:
5102:
5099:
5097:
5094:
5091:
5087:
5084:
5082:
5079:
5077:
5074:
5072:
5069:
5067:
5064:
5062:
5061:Darvadstrocel
5059:
5057:
5054:
5052:
5049:
5047:
5044:
5042:
5039:
5037:
5034:
5032:
5029:
5027:
5024:
5022:
5019:
5017:
5014:
5013:
5011:
5007:
4997:
4994:
4992:
4989:
4987:
4984:
4980:
4977:
4975:
4972:
4971:
4970:
4969:
4968:TNF inhibitor
4965:
4961:
4958:
4956:
4953:
4952:
4951:
4950:
4946:
4945:
4943:
4940:
4935:
4925:
4922:
4920:
4917:
4916:
4914:
4912:
4908:
4898:
4895:
4893:
4890:
4888:
4885:
4883:
4880:
4878:
4875:
4873:
4870:
4868:
4865:
4863:
4860:
4858:
4855:
4853:
4850:
4848:
4845:
4843:
4840:
4838:
4835:
4833:
4830:
4828:
4825:
4823:
4820:
4818:
4815:
4813:
4810:
4808:
4805:
4803:
4800:
4799:
4797:
4793:
4786:
4782:
4781:
4777:
4776:
4771:
4768:
4766:
4763:
4761:
4758:
4757:
4756:
4755:
4751:
4750:
4745:
4742:
4741:
4740:
4739:
4735:
4731:
4728:
4727:
4726:
4725:
4721:
4717:
4714:
4712:
4709:
4708:
4707:
4706:
4702:
4698:
4695:
4693:
4690:
4688:
4685:
4684:
4683:
4682:
4678:
4674:
4671:
4670:
4669:
4666:
4665:
4660:
4657:
4655:
4652:
4651:
4650:
4649:
4645:
4641:
4638:
4637:
4636:
4635:
4634:CD147/Basigin
4631:
4627:
4624:
4623:
4622:
4621:
4617:
4613:
4610:
4609:
4608:
4607:
4603:
4599:
4596:
4594:
4591:
4590:
4589:
4588:
4584:
4580:
4577:
4575:
4572:
4571:
4570:
4569:
4565:
4561:
4558:
4556:
4553:
4551:
4548:
4545:
4541:
4538:
4536:
4533:
4532:
4531:
4530:
4526:
4522:
4519:
4518:
4517:
4516:
4512:
4508:
4505:
4504:
4503:
4502:
4498:
4494:
4491:
4489:
4486:
4484:
4481:
4480:
4479:
4478:
4474:
4470:
4467:
4465:
4462:
4460:
4457:
4455:
4454:Muromonab-CD3
4452:
4451:
4450:
4449:
4445:
4444:
4442:
4436:
4428:
4425:
4424:
4423:
4422:
4418:
4417:
4412:
4409:
4407:
4404:
4403:
4402:
4401:
4397:
4393:
4389:
4388:
4383:
4380:
4379:
4378:
4377:
4373:
4372:
4367:
4364:
4363:
4362:
4361:
4357:
4356:
4351:
4348:
4347:
4346:
4345:
4341:
4340:
4335:
4332:
4331:
4330:
4329:
4328:Interleukin 5
4325:
4324:
4319:
4316:
4314:
4311:
4309:
4308:Tildrakizumab
4306:
4304:
4301:
4299:
4296:
4294:
4291:
4289:
4286:
4284:
4281:
4279:
4276:
4274:
4271:
4269:
4266:
4264:
4261:
4259:
4256:
4254:
4251:
4249:
4246:
4244:
4241:
4239:
4236:
4234:
4231:
4229:
4226:
4224:
4221:
4219:
4216:
4214:
4211:
4210:
4209:
4208:
4204:
4203:
4198:
4195:
4193:
4190:
4188:
4185:
4183:
4180:
4178:
4175:
4173:
4170:
4169:
4168:
4167:
4163:
4162:
4157:
4154:
4153:
4152:
4151:
4147:
4146:
4144:
4142:(noncellular)
4138:
4135:
4133:
4129:
4126:
4124:
4120:
4117:
4115:Extracellular
4113:
4103:
4100:
4098:
4095:
4093:
4090:
4088:
4085:
4083:
4082:Ridaforolimus
4080:
4078:
4075:
4074:
4072:
4070:
4066:
4060:
4057:
4056:
4054:
4052:
4048:
4045:
4041:Intracellular
4039:
4027:
4024:
4023:
4022:
4021:
4017:
4015:
4012:
4010:
4007:
4005:
4002:
4001:
3999:
3997:
3993:
3987:
3984:
3982:
3979:
3978:
3973:
3970:
3968:
3965:
3963:
3960:
3958:
3955:
3954:
3953:
3952:
3948:
3944:
3940:
3939:
3937:
3934:
3928:
3924:
3916:
3913:
3912:
3911:
3910:
3906:
3905:
3900:
3899:Teriflunomide
3897:
3895:
3892:
3891:
3889:
3888:
3884:
3883:
3878:
3875:
3873:
3870:
3869:
3868:
3867:
3863:
3862:
3860:
3858:
3854:
3851:
3847:Intracellular
3845:
3840:
3836:
3832:
3825:
3820:
3818:
3813:
3811:
3806:
3805:
3802:
3790:
3787:
3785:
3782:
3780:
3777:
3775:
3772:
3771:
3769:
3765:
3755:
3752:
3750:
3747:
3745:
3742:
3741:
3739:
3735:
3729:
3726:
3724:
3721:
3719:
3716:
3714:
3711:
3709:
3706:
3704:
3701:
3699:
3696:
3694:
3691:
3689:
3686:
3685:
3683:
3681:
3677:
3671:
3668:
3666:
3663:
3661:
3658:
3656:
3653:
3651:
3648:
3646:
3643:
3641:
3638:
3637:
3635:
3633:
3629:
3623:
3620:
3618:
3615:
3613:
3610:
3608:
3605:
3603:
3600:
3599:
3597:
3595:
3591:
3588:
3584:
3578:
3575:
3571:
3568:
3567:
3565:
3564:
3562:
3558:
3552:
3551:Teriflunomide
3549:
3547:
3544:
3542:
3539:
3537:
3534:
3531:
3527:
3524:
3522:
3519:
3517:
3514:
3512:
3509:
3507:
3504:
3502:
3499:
3497:
3494:
3492:
3489:
3487:
3484:
3482:
3479:
3477:
3474:
3472:
3469:
3467:
3464:
3462:
3459:
3458:
3456:
3452:
3446:
3443:
3439:
3436:
3434:
3431:
3429:
3426:
3425:
3424:Radiological
3423:
3419:
3416:
3415:
3413:
3409:
3406:
3404:
3401:
3400:
3398:
3397:
3394:
3391:
3387:
3384:
3383:
3382:
3379:
3378:
3376:
3372:
3366:
3363:
3361:
3358:
3356:
3353:
3351:
3348:
3346:
3343:
3341:
3338:
3336:
3333:
3331:
3328:
3326:
3323:
3321:
3318:
3316:
3313:
3312:
3310:
3308:
3304:
3300:
3292:
3287:
3285:
3280:
3278:
3273:
3272:
3269:
3261:
3257:
3252:
3247:
3242:
3237:
3233:
3229:
3228:Int J Mol Sci
3225:
3220:
3219:
3215:
3198:
3194:
3192:
3186:
3180:
3177:
3164:
3160:
3156:
3150:
3147:
3133:
3129:
3127:
3122:
3116:
3114:
3110:
3097:
3093:
3089:
3083:
3080:
3060:
3053:
3052:"lay-summary"
3039:
3032:
3026:
3023:
3007:
3003:
2999:
2992:
2986:
2983:
2967:
2963:
2956:
2950:
2947:
2942:
2938:
2934:
2930:
2926:
2922:
2918:
2914:
2907:
2904:
2888:
2884:
2877:
2871:
2868:
2855:
2851:
2850:
2845:
2838:
2836:
2832:
2819:
2815:
2814:
2809:
2803:
2800:
2795:
2791:
2787:
2783:
2779:
2775:
2771:
2767:
2760:
2757:
2752:
2748:
2744:
2740:
2736:
2732:
2728:
2724:
2717:
2714:
2709:
2705:
2701:
2697:
2693:
2689:
2685:
2681:
2674:
2671:
2666:
2662:
2658:
2654:
2650:
2646:
2639:
2637:
2633:
2628:
2624:
2619:
2614:
2610:
2606:
2602:
2598:
2594:
2587:
2584:
2579:
2575:
2570:
2565:
2561:
2557:
2553:
2546:
2543:
2538:
2534:
2529:
2524:
2520:
2516:
2512:
2505:
2502:
2497:
2493:
2489:
2485:
2480:
2475:
2472:(7): 3893–5.
2471:
2467:
2466:
2461:
2454:
2451:
2446:
2442:
2438:
2434:
2430:
2426:
2422:
2418:
2411:
2408:
2403:
2399:
2395:
2391:
2384:
2381:
2378:
2374:
2371:
2354:
2350:
2346:
2339:
2332:
2330:
2328:
2324:
2311:
2307:
2300:
2297:
2294:
2290:
2287:
2283:
2279:
2276:
2262:
2255:
2249:
2246:
2233:
2226:
2220:
2217:
2204:
2200:
2196:
2190:
2187:
2174:
2170:
2166:
2160:
2157:
2152:
2148:
2144:
2140:
2136:
2132:
2129:(8): 745–58.
2128:
2124:
2116:
2113:
2108:
2104:
2099:
2094:
2090:
2086:
2082:
2075:
2072:
2059:
2055:
2051:
2045:
2042:
2029:
2025:
2023:
2017:
2010:
2007:
2002:
1998:
1993:
1988:
1984:
1980:
1976:
1969:
1967:
1965:
1961:
1948:
1941:
1939:
1935:
1919:
1915:
1908:
1902:
1899:
1894:
1890:
1886:
1882:
1878:
1871:
1868:
1863:
1859:
1854:
1849:
1844:
1839:
1835:
1831:
1827:
1820:
1818:
1816:
1812:
1807:
1803:
1799:
1795:
1788:
1785:
1781:
1780:public domain
1762:
1758:
1756:
1750:
1744:
1742:
1740:
1738:
1736:
1732:
1719:
1715:
1714:Fierce Pharma
1711:
1704:
1701:
1688:
1684:
1680:
1673:
1670:
1657:
1653:
1649:
1643:
1640:
1627:
1623:
1619:
1612:
1610:
1608:
1604:
1588:
1584:
1577:
1571:
1568:
1554:
1550:
1548:
1543:
1537:
1535:
1533:
1531:
1529:
1527:
1525:
1523:
1521:
1519:
1515:
1502:
1498:
1494:
1488:
1486:
1484:
1482:
1480:
1478:
1476:
1474:
1472:
1470:
1468:
1466:
1462:
1449:
1445:
1441:
1435:
1432:
1419:
1415:
1414:
1413:Health Canada
1409:
1403:
1400:
1387:
1383:
1379:
1373:
1370:
1357:
1353:
1349:
1343:
1340:
1328:
1324:
1320:
1314:
1311:
1298:
1294:
1290:
1284:
1281:
1268:
1264:
1260:
1259:"Tyruko EPAR"
1254:
1252:
1250:
1246:
1230:
1223:
1217:
1215:
1213:
1211:
1209:
1205:
1198:
1196:
1193:
1191:
1187:
1179:
1177:
1173:
1171:
1167:
1163:
1162:Health Canada
1159:
1157:
1152:
1150:
1146:
1142:
1138:
1134:
1126:
1121:
1119:
1113:
1111:
1108:
1104:
1099:
1097:
1093:
1089:
1085:
1081:
1077:
1073:
1069:
1065:
1061:
1057:
1053:
1045:
1043:
1041:
1037:
1036:Animal models
1033:
1029:
1025:
1021:
1011:
1009:
1004:
1002:
998:
994:
991:gene, and in
990:
986:
982:
978:
974:
970:
969:T-lymphocytes
966:
962:
958:
950:
948:
946:
942:
939:to move into
938:
934:
930:
927:
920:
915:
908:
906:
903:
900:
898:
894:
890:
886:
882:
878:
874:
869:
867:
863:
859:
855:
851:
847:
846:liver enzymes
843:
839:
835:
831:
827:
823:
820:
814:
812:
808:
804:
803:boxed warning
796:
790:
787:
786:
785:
783:
778:
776:
770:
767:
759:
757:
755:
751:
747:
742:
738:
734:
730:
725:
722:
718:
716:
712:
708:
705:
701:
697:
694:
690:
687:
683:
679:
675:
671:
661:
654:
648:
644:
642:
638:
633:
625:
621:
617:
616:
614:
605:
601:
594:
593:ChEMBL1201607
590:
589:
587:
585:
581:
574:
570:
569:
567:
565:
561:
554:
550:
549:
547:
545:
541:
534:
533:
531:
529:
525:
518:
514:
513:
511:
509:
505:
498:
494:
493:
491:
489:
485:
480:
476:
474:
467:
463:
461:
457:
453:
449:
442:
440: Rx-only
433:
430:
418:
415:
405:
402:
393:
390:
380:
379:
377:
375:
371:
366:
358:
353:
350:
349:
347:
345:
341:
338:
335:
333:
327:
321:
312:
311:
309:
307:
301:
294:
289:
280:
279:
277:
275:
271:
267:
263:
261:
257:
253:
249:
247:
243:
239:
235:
233:
229:
225:
221:
217:
215:
211:
208:Clinical data
206:
203:
199:
197:
193:
189:
185:
182:
180:
176:
172:
170:
166:
163:
159:
153:
149:
145:
139:
134:
126:
113:
109:
106:November 2018
98:
95:
91:
88:
84:
81:
77:
74:
70:
67: –
66:
65:"Natalizumab"
62:
61:Find sources:
56:
52:
46:
45:
41:
37:
32:This article
30:
21:
20:
6184:Risankizumab
6169:Lebrikizumab
6149:Clazakizumab
6139:Anrukinzumab
6118:Tralokinumab
6034:Otelixizumab
6014:
6006:
6005:
5975:Tregalizumab
5960:Tislelizumab
5930:Satralizumab
5910:Rontalizumab
5905:Retifanlimab
5880:Plozalizumab
5860:Pateclizumab
5855:Pascolizumab
5850:Ozoralizumab
5829:
5800:Lampalizumab
5790:Inebilizumab
5780:Fontolizumab
5730:Camrelizumab
5725:Benralizumab
5720:Atezolizumab
5706:
5649:Clenoliximab
5550:
5534:Bertilimumab
5529:
5518:Tremelimumab
5498:
5421:Mavrilimumab
5411:Lirentelimab
5406:Lerdelimumab
5381:Fresolimumab
5321:Atorolimumab
5299:
5231:Upadacitinib
5191:Satralizumab
5176:Ritlecitinib
5171:Risankizumab
4966:
4947:
4887:Teprotumumab
4837:Inebilizumab
4832:Fontolizumab
4812:Atorolimumab
4780:T-lymphocyte
4778:
4752:
4736:
4722:
4710:
4703:
4692:Lerdelimumab
4687:Bertilimumab
4679:
4667:
4646:
4632:
4618:
4604:
4585:
4566:
4550:Pascolizumab
4535:Obinutuzumab
4527:
4513:
4499:
4483:Clenoliximab
4475:
4459:Otelixizumab
4446:
4419:
4406:Lebrikizumab
4390:
4374:
4358:
4342:
4326:
4283:Satralizumab
4273:Risankizumab
4205:
4164:
4148:
4140:Serum target
4092:Temsirolimus
4018:
4009:Pomalidomide
4004:Lenalidomide
3962:Pimecrolimus
3941:
3915:Methotrexate
3907:
3885:
3872:Azathioprine
3864:
3849:(initiation)
3632:Inflammatory
3520:
3511:Mitoxantrone
3345:Incontinence
3231:
3227:
3201:. Retrieved
3188:
3179:
3167:. Retrieved
3158:
3149:
3136:. Retrieved
3124:
3100:. Retrieved
3082:
3066:. Retrieved
3042:. Retrieved
3025:
3013:. Retrieved
3001:
2997:
2985:
2973:. Retrieved
2949:
2916:
2912:
2906:
2894:. Retrieved
2870:
2858:. Retrieved
2847:
2822:. Retrieved
2811:
2802:
2769:
2765:
2759:
2726:
2722:
2716:
2683:
2679:
2673:
2648:
2644:
2600:
2596:
2586:
2559:
2555:
2545:
2518:
2514:
2504:
2469:
2463:
2453:
2420:
2416:
2410:
2393:
2389:
2383:
2360:. Retrieved
2314:. Retrieved
2299:
2265:. Retrieved
2248:
2236:. Retrieved
2219:
2207:. Retrieved
2189:
2177:. Retrieved
2168:
2159:
2126:
2122:
2115:
2088:
2084:
2074:
2062:. Retrieved
2044:
2032:. Retrieved
2028:the original
2019:
2009:
1982:
1978:
1951:. Retrieved
1925:. Retrieved
1918:the original
1901:
1876:
1870:
1833:
1829:
1797:
1793:
1787:
1765:. Retrieved
1752:
1722:. Retrieved
1713:
1703:
1691:. Retrieved
1672:
1660:. Retrieved
1656:the original
1642:
1630:. Retrieved
1594:. Retrieved
1587:the original
1570:
1557:. Retrieved
1545:
1505:. Retrieved
1496:
1452:. Retrieved
1443:
1434:
1422:. Retrieved
1411:
1402:
1390:. Retrieved
1381:
1372:
1360:. Retrieved
1351:
1342:
1330:. Retrieved
1322:
1313:
1301:. Retrieved
1292:
1283:
1271:. Retrieved
1262:
1236:. Retrieved
1194:
1183:
1174:
1160:
1153:
1130:
1127:Legal status
1117:
1100:
1076:azathioprine
1049:
1046:Interactions
1017:
1005:
965:inflammatory
954:
923:
904:
901:
870:
824:
815:
800:
779:
771:
763:
760:Medical uses
726:
723:
719:
707:immune cells
704:inflammatory
691:against the
673:
669:
668:
657:
651:
470:Elimination
374:Legal status
368:Legal status
274:License data
144:Fab fragment
142:Natalizumab
125:
103:
93:
86:
79:
72:
60:
40:verification
33:
6280:from market
6250:Lemalesomab
6245:Fanolesomab
6240:Besilesomab
6179:Perakizumab
6164:Mirikizumab
6154:Gevokizumab
6144:Bimekizumab
6123:Ustekinumab
6108:Secukinumab
6093:Fezakinumab
6088:Canakinumab
6083:Briakinumab
6058:Interleukin
6011:Dostarlimab
5990:Visilizumab
5985:Vedolizumab
5980:Vatelizumab
5970:Toralizumab
5965:Tocilizumab
5950:Teclistamab
5925:Samalizumab
5915:Rovelizumab
5895:Ravulizumab
5875:Pidilizumab
5870:Pexelizumab
5835:Ocrelizumab
5830:Natalizumab
5820:Mepolizumab
5810:Ligelizumab
5805:Letolizumab
5775:Etrolizumab
5765:Epratuzumab
5735:Cedelizumab
5689:Vapaliximab
5684:Teneliximab
5674:Lumiliximab
5659:Gomiliximab
5644:Basiliximab
5616:Vepalimomab
5601:Nerelimomab
5586:Gavilimomab
5581:Faralimomab
5576:Elsilimomab
5551:Combination
5544:Zanolimumab
5539:Ontamalimab
5487:Ulocuplumab
5482:Tezepelumab
5472:Sifalimumab
5452:Pamrevlumab
5431:Morolimumab
5426:Metelimumab
5396:Lanadelumab
5331:Avdoralimab
5316:Anifrolumab
5226:Tofacitinib
5166:Ravulizumab
5156:Pirfenidone
5146:Peficitinib
5046:Canakinumab
5036:Briakinumab
5026:Bimekizumab
5021:Baricitinib
4986:Aflibercept
4897:Vepalimomab
4892:Vapaliximab
4867:Rovelizumab
4857:Pexelizumab
4847:Morolimumab
4822:Cedelizumab
4807:Anifrolumab
4802:Alemtuzumab
4760:Basiliximab
4730:Tocilizumab
4716:Vedolizumab
4711:Natalizumab
4697:Metelimumab
4640:Gavilimomab
4598:Toralizumab
4593:Teneliximab
4579:Lumiliximab
4574:Gomiliximab
4560:Ublituximab
4540:Ocrelizumab
4493:Zanolimumab
4469:Visilizumab
4427:Secukinumab
4411:Ustekinumab
4382:Elsilimomab
4366:Faralimomab
4334:Mepolizumab
4318:Ustekinumab
4313:Tocilizumab
4288:Secukinumab
4238:Canakinumab
4228:Briakinumab
4223:Bimekizumab
4218:Basiliximab
4207:Interleukin
4197:Nerelimomab
4102:Zotarolimus
4043:(reception)
4014:Thalidomide
3972:Voclosporin
3957:Ciclosporin
3951:Calcineurin
3947:Cyclophilin
3894:Leflunomide
3890:inhibitors
3526:Ocrelizumab
3521:Natalizumab
3466:Alemtuzumab
3203:26 November
3015:18 December
2824:5 September
2370:lay summary
2345:Biogen Idec
2275:lay-summary
2179:29 November
2034:22 December
1953:21 December
1724:20 November
1180:Biosimilars
1072:astrocytoma
997:osteopontin
993:parenchymal
881:anaphylaxis
850:rechallenge
775:monotherapy
696:α4-integrin
670:Natalizumab
497:189261-10-7
482:Identifiers
477:11 ± 4 days
337:Intravenous
293:Natalizumab
260:MedlinePlus
232:Biosimilars
223:Other names
214:Trade names
130:Natalizumab
34:needs more
6333:Categories
6210:Lokivetmab
6203:Veterinary
6189:Spesolimab
6174:Olokizumab
6159:Ixekizumab
6103:Guselkumab
6098:Fletikumab
6078:Brazikumab
6073:Bermekimab
6044:Sutimlimab
6018:Ibalizumab
5955:Teplizumab
5935:Siplizumab
5920:Ruplizumab
5900:Reslizumab
5890:Quilizumab
5845:Omalizumab
5795:Itolizumab
5785:Frexalimab
5760:Efalizumab
5755:Eculizumab
5750:Daclizumab
5715:Aselizumab
5710:Apolizumab
5679:Priliximab
5664:Infliximab
5606:Odulimomab
5596:Maslimomab
5591:Inolimomab
5571:Afelimomab
5508:Durvalumab
5503:Ipilimumab
5492:Varlilumab
5462:Relatlimab
5457:Placulumab
5401:Lenzilumab
5376:Emapalumab
5361:Cemiplimab
5346:Brodalumab
5341:Bleselumab
5311:Adalimumab
5216:Sutimlimab
5211:Spesolimab
5196:Siltuximab
5136:Olokizumab
5126:Ixekizumab
5121:Itacitinib
5111:Guselkumab
5106:Fingolimod
5101:Filgotinib
5051:Crovalimab
5041:Brodalumab
5031:Blisibimod
4996:Rilonacept
4979:Opinercept
4974:Etanercept
4960:Belatacept
4911:Polyclonal
4872:Siplizumab
4862:Reslizumab
4852:Ofatumumab
4842:Maslimomab
4827:Emapalumab
4770:Inolimomab
4765:Daclizumab
4744:Odulimomab
4659:Ruplizumab
4654:Frexalimab
4612:Aselizumab
4507:Efalizumab
4464:Teplizumab
4360:Interferon
4350:Omalizumab
4303:Spesolimab
4293:Siltuximab
4268:Rilonacept
4263:Olokizumab
4253:Ixekizumab
4248:Guselkumab
4243:Daclizumab
4233:Brodalumab
4192:Infliximab
4177:Afelimomab
4172:Adalimumab
4156:Eculizumab
4132:Monoclonal
4123:Antibodies
4097:Umirolimus
4077:Everolimus
4026:Apremilast
3986:Gusperimus
3967:Tacrolimus
3935:inhibitors
3927:Macrolides
3909:antifolate
3680:Hereditary
3594:Autoimmune
3570:Daclizumab
3506:Laquinimod
3486:Fingolimod
3471:Cladribine
3445:Frexalimab
3330:Dysarthria
3320:Depression
3234:(5): 940.
2390:Rev Neurol
1332:22 October
1199:References
1145:first-line
1084:infliximab
1001:leukocytes
739:, another
711:intestines
684:. It is a
641:Molar mass
553:3JB47N2Q2P
528:ChemSpider
488:CAS Number
76:newspapers
6290:Phase III
6278:Withdrawn
6255:Sulesomab
6132:Humanized
6113:Sirukumab
5945:Talizumab
5770:Erlizumab
5699:Humanized
5669:Keliximab
5654:Galiximab
5513:Nivolumab
5477:Tabalumab
5467:Sarilumab
5441:Oleclumab
5436:Namilumab
5416:Lirilumab
5391:Ianalumab
5386:Golimumab
5371:Eldelumab
5366:Dupilumab
5336:Belimumab
5306:Abrilumab
5206:Sirukumab
5201:Siponimod
5186:Sarilumab
5161:Ponesimod
5131:Netakimab
5116:Iptacopan
5096:Etrasimod
5056:Danicopan
4991:Alefacept
4955:Abatacept
4877:Talizumab
4817:Begelomab
4673:Belimumab
4626:Galiximab
4555:Rituximab
4521:Erlizumab
4488:Keliximab
4298:Sirukumab
4278:Sarilumab
4258:Netakimab
4187:Golimumab
4087:Sirolimus
3546:Siponimod
3541:Ponesimod
3399:Clinical
3350:Nystagmus
3335:Dysphagia
3138:25 August
2496:206866717
2417:Neurology
2064:31 August
1767:25 August
1693:31 August
1632:31 August
1596:31 August
1424:25 August
1392:25 August
1362:25 August
1293:Drugs.com
1273:6 October
1238:25 August
1170:physician
1149:alosetron
1020:addressin
959:-causing
926:humanized
842:bilirubin
766:indicated
686:humanized
472:half-life
330:Routes of
304:Pregnancy
252:Monograph
246:Drugs.com
184:Humanized
6323:Medicine
5631:Chimeric
5523:Urelumab
5446:Oxelumab
5356:Carlumab
5326:Avelumab
5275:for the
5141:Ozanimod
5016:Avacopan
5009:Unsorted
4795:Unsorted
4705:Integrin
4438:Cellular
4213:Anakinra
4059:Anakinra
3981:Abetimus
3833: /
3536:Ozanimod
3325:Diplopia
3260:28468254
3197:Archived
3163:Archived
3132:Archived
3096:Archived
3059:Archived
3006:Archived
2966:Archived
2941:22339176
2933:18090880
2887:Archived
2860:13 March
2854:Archived
2818:Archived
2794:18131415
2786:17434098
2751:25003597
2743:17122725
2708:28808262
2700:17521672
2665:17136224
2627:16510746
2578:15947078
2537:15947079
2488:18235044
2445:39916466
2437:15851719
2402:17876741
2373:Archived
2362:11 April
2353:Archived
2310:Archived
2289:Archived
2278:Archived
2273: ;
2267:14 April
2203:Archived
2173:Archived
2151:15639613
2143:21777829
2107:22591293
2058:Archived
2001:15947080
1893:21975773
1862:18360634
1806:18354844
1761:Archived
1718:Archived
1687:Archived
1626:Archived
1622:Medscape
1553:Archived
1501:Archived
1497:DailyMed
1448:Archived
1418:Archived
1386:Archived
1356:Archived
1297:Archived
1267:Archived
1229:Archived
1068:sequelae
1060:JC virus
933:integrin
919:antibody
885:headache
858:sequelae
834:jaundice
811:JC virus
660:(verify)
508:DrugBank
344:ATC code
306:category
288:DailyMed
202:integrin
200:alpha-4
155:.
6225:lesions
6000:TGN1412
5885:PRO 140
4937:-cept (
3566:Former
3340:Fatigue
3251:5454853
3169:24 July
3102:9 March
3090:. U.S.
3068:4 April
3044:2 April
2975:2 April
2896:9 March
2881:. U.S.
2618:1934511
2316:5 April
2238:5 April
2209:5 April
2197:. U.S.
1927:9 March
1853:1936307
1662:18 July
1652:ECTRIMS
1382:TGA eBS
1114:History
1024:venules
961:lesions
957:symptom
873:fatigue
674:Tysabri
517:DB00108
431:Rx-only
428:WARNING
399::
360:)
354: (
352:L04AG03
319: C
290::
266:a605006
90:scholar
55:removed
6309:Portal
6273:WHO-EM
6015:Other:
4949:CTLA-4
4939:Fusion
4440:target
4421:IL-17A
4398:, and
3931:other
3315:Ataxia
3258:
3248:
3159:PMLive
3074:
2939:
2931:
2792:
2784:
2749:
2741:
2706:
2698:
2663:
2625:
2615:
2576:
2535:
2494:
2486:
2443:
2435:
2400:
2149:
2141:
2105:
1999:
1891:
1860:
1850:
1804:
989:VCAM-1
941:organs
889:nausea
584:ChEMBL
573:D06886
425:
412:
401:℞-only
387:
286:
196:Target
186:(from
179:Source
92:
85:
78:
71:
63:
6233:Mouse
6066:Human
5564:Mouse
5530:Other
5293:Human
4738:LFA-1
4648:CD154
4501:CD11a
4400:IL-23
4396:IL-13
4392:IL-12
3996:IMiDs
3767:Other
3737:Other
3193:(FDA)
3189:U.S.
3128:(EMA)
3062:(PDF)
3055:(PDF)
3034:(PDF)
3009:(PDF)
2994:(PDF)
2969:(PDF)
2958:(PDF)
2937:S2CID
2890:(PDF)
2879:(PDF)
2790:S2CID
2747:S2CID
2704:S2CID
2492:S2CID
2465:Blood
2441:S2CID
2356:(PDF)
2341:(PDF)
2257:(PDF)
2228:(PDF)
2147:S2CID
2024:(FDA)
2020:U.S.
1921:(PDF)
1910:(PDF)
1757:(FDA)
1753:U.S.
1683:WebMD
1590:(PDF)
1579:(PDF)
1559:4 May
1549:(EMA)
1507:4 May
1454:4 May
1444:(emc)
1303:4 May
1232:(PDF)
1225:(PDF)
897:fever
893:colds
866:death
830:liver
188:mouse
97:JSTOR
83:books
4668:BLyS
4620:CD80
4587:CD40
4568:CD23
4529:CD20
4515:CD18
4376:IL-6
4069:mTOR
3943:FKBP
3933:IL-2
3360:Pain
3256:PMID
3205:2023
3171:2023
3140:2023
3104:2008
3070:2008
3046:2008
3017:2010
2977:2008
2929:PMID
2898:2008
2862:2008
2826:2008
2782:PMID
2739:PMID
2696:PMID
2661:PMID
2623:PMID
2574:PMID
2533:PMID
2484:PMID
2433:PMID
2398:PMID
2364:2008
2349:Élan
2347:and
2318:2008
2269:2008
2240:2008
2211:2008
2181:2019
2139:PMID
2103:PMID
2066:2010
2036:2008
1997:PMID
1955:2008
1929:2008
1889:PMID
1858:PMID
1802:PMID
1769:2023
1726:2018
1695:2010
1664:2019
1634:2010
1598:2010
1561:2020
1509:2020
1456:2020
1426:2023
1394:2023
1364:2023
1334:2023
1305:2020
1275:2023
1240:2023
1090:for
1082:and
1008:CD34
955:The
875:and
844:and
792:MRI.
713:and
680:and
564:KEGG
544:UNII
535:none
454:data
242:AHFS
169:Type
152:4IRZ
69:news
38:for
4681:CAT
4477:CD4
4448:CD3
4166:TNF
3839:L04
3246:PMC
3236:doi
3002:142
2921:doi
2774:doi
2731:doi
2688:doi
2684:259
2653:doi
2613:PMC
2605:doi
2601:354
2564:doi
2560:353
2523:doi
2519:353
2474:doi
2470:111
2425:doi
2131:doi
2093:doi
2089:366
2054:FDA
1987:doi
1983:353
1881:doi
1848:PMC
1838:doi
1327:FDA
1030:in
864:or
860:of
609:EPA
464:n/a
414:POM
357:WHO
148:PDB
6335::
6286::
6009::
5553::
5532::
5501::
5304::
4394:,
3254:.
3244:.
3232:18
3230:.
3226:.
3187:.
3157:.
3123:.
3112:^
3057:.
3036:.
3000:.
2996:.
2935:.
2927:.
2917:14
2915:.
2852:.
2846:.
2834:^
2810:.
2788:.
2780:.
2768:.
2745:.
2737:.
2727:12
2725:.
2702:.
2694:.
2682:.
2659:.
2649:42
2647:.
2635:^
2621:.
2611:.
2599:.
2595:.
2572:.
2558:.
2554:.
2531:.
2517:.
2513:.
2490:.
2482:.
2468:.
2462:.
2439:.
2431:.
2421:64
2419:.
2394:45
2368:;
2351:.
2343:.
2326:^
2308:.
2284:,
2259:.
2230:.
2167:.
2145:.
2137:.
2127:10
2125:.
2101:.
2087:.
2083:.
2052:.
2018:.
1995:.
1981:.
1977:.
1963:^
1937:^
1912:.
1887:.
1856:.
1846:.
1832:.
1828:.
1814:^
1798:17
1796:.
1751:.
1734:^
1716:.
1712:.
1685:.
1681:.
1650:.
1624:.
1620:.
1606:^
1581:.
1544:.
1517:^
1495:.
1464:^
1442:.
1410:.
1384:.
1380:.
1350:.
1325:.
1321:.
1291:.
1261:.
1248:^
1227:.
1207:^
1172:.
1078:,
891:,
887:,
883:,
868:.
777:.
717:.
436:EU
421:US
408:UK
396:CA
389:S4
383:AU
315:AU
283:US
57:.
6311::
5841:)
5837:(
5448:§
5265:e
5258:t
5251:v
5092:)
5088:(
4941:)
4787:)
4783:(
4546:)
4542:(
3949:/
3945:/
3929:/
3841:)
3837:(
3823:e
3816:t
3809:v
3532:)
3528:(
3290:e
3283:t
3276:v
3262:.
3238::
3207:.
3173:.
3142:.
3106:.
3072:.
3048:.
3019:.
2979:.
2943:.
2923::
2900:.
2864:.
2828:.
2796:.
2776::
2770:6
2753:.
2733::
2710:.
2690::
2667:.
2655::
2629:.
2607::
2580:.
2566::
2539:.
2525::
2498:.
2476::
2447:.
2427::
2404:.
2366:.
2320:.
2271:.
2242:.
2213:.
2183:.
2153:.
2133::
2109:.
2095::
2068:.
2038:.
2003:.
1989::
1957:.
1931:.
1895:.
1883::
1864:.
1840::
1834:3
1808:.
1782:.
1771:.
1728:.
1697:.
1666:.
1636:.
1600:.
1563:.
1511:.
1458:.
1428:.
1396:.
1366:.
1336:.
1307:.
1277:.
1242:.
611:)
607:(
438::
423::
410::
385::
317::
244:/
190:)
108:)
104:(
94:·
87:·
80:·
73:·
47:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
